ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: Correlation with clinical outcome

Haematologica

Volumn 96, Issue 10, 2011, Pages 1521-1527

  Yang, Shangbin ^a   Jin, Ming ^a   Lin, Shili ^a   Cataland, Spero ^b   Wu, Haifeng ^a,b  

^a Texas A and M University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAMTS13; Biomarker; Prognosis; Thrombotic thrombocytopenic purpura

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MORTALITY; PLASMAPHERESIS; REFERENCE VALUE; REMISSION; TREATMENT RESPONSE;

ADAM PROTEINS; ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053633801     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.042945     Document Type: Article

References (26)

1. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927-35.
2. Peyvandi F. The role of ADAMTS13 in the new pathogenesis of TTP. Hematology. 2005;10 (Suppl 1):47-8.
3. Sadler JE. Thrombotic thrombocytopenic purpura: a moving target. Hematology Am Soc Hematol Educ Program. 2006:415-20.
4. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.[comment]. Nature. 2001;413(6855):488-94.
5. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-61.
6. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339(22):1578-84.
7. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424.
8. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585-94.
9. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005;106(1): 11-7.
10. Jin M, Cataland SR, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization timeof- flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost. 2006;4(2):333-8.
11. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
12. Whitelock JL, Nolasco L, Bernardo A, Moake J, Dong JF, Cruz MA. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost. 2004;2(3):485-91.
13. Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost. 2004;91(4):806-11.
14. Groot E, Hulstein JJ, Rison CN, de Groot PG, Fijnheer R. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(3):698-9.
15. Rieger M, Ferrari S, Kremer Hovinga JA, Konetschny C, Herzog A, Koller L, et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost. 2006;95(2):212-20.
16. Liu F, Feys HB, Dong N, Zhao Y, Ruan C. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Thromb Haemost. 2006;95(4):749-50.
17. Cataland SR, Jin M, Smith E, Stanek M, Wu HM. Full evaluation of an acquired case of thrombotic thrombocytopenic purpura following the surgical resection of glioblastoma multiforme. J Thromb Haemost. 2006;4(12):2733-7.
18. Shelat SG, Smith P, Ai J, Zheng XL. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707-17.
19. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol. 2008;141(5):651-8.
20. Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, et al. Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007;139(3):486-93.
21. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol. 1997;54(2):102-7.
22. Tuncer HH, Oster RA, Huang ST, Marques MB. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion. 2007;47(1):107-14.
23. Wyllie BF, Garg AX, Macnab J, Rock GA, Clark WF. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol. 2006;132(2):204-9.
24. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher. 1998;13(1):16-9.
25. Cataland SR, Jin M, Lin S, Kraut EH, George JN, Wu HM. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol. 2008;83(12):911-5.
26. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106(6):1932-7.